Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: What I'm looking for

That could be possible if there is no restrcition to the amount of shares purchased by the company since it would be a private sale rather than on the open market. Only drawback is the cash spent in doing so; they structured the deal IMO to conserve cash for the upcoming investments they plan at the end of the month and further M&A...spending 4-6 Million on Swartz would hinder that.

JMO

Share
New Message
Please login to post a reply